When will CagriSema be approved? No date has been announced. Novo Nordisk submitted the application to the FDA on 18 December 2025, and its third-quarter investor materials, published on 4 November 2026, point to a decision in the fourth quarter of 2026 and a US launch in early 2027. CagriSema is not approved in the United States today.
The argument of this piece is that the approval date is the least uncertain part of the CagriSema story. Three company documents across eleven months give the same window, and the standard FDA review clock, counted from the filing, lands in mid-December 2026. The open question is what the drug will be once it is approved. CagriSema reached the FDA as the first weekly combination of a GLP-1 medicine and an amylin analogue, with 20.4% average weight loss in its main trial. Two months after the filing it failed to match tirzepatide in the only head-to-head trial run at full strength. Ozemback's view is that the label, the price and the supply plan will matter more than the day the letter arrives.
Nothing below is medical advice, and this page does not tell anyone whether to take, wait for or switch to any medicine. Doses appear only as the names of trial arms, the way Novo Nordisk and the New England Journal of Medicine report them. Every date and figure comes from a source read on 12 November 2026 and listed at the foot of the page. Company guidance about an FDA decision is a forecast, and the agency can approve, delay or refuse. Ozemback has no commercial relationship with Novo Nordisk or Eli Lilly. For compounds that are not FDA-approved medicines, the regulatory status of each one is in the Ozemback peptide tracker and in the compound files.
When will CagriSema be approved by the FDA?
CagriSema has no announced FDA approval date as of 12 November 2026, and the agency has not approved it. Novo Nordisk's guidance has been consistent. The filing announcement of 18 December 2025 said the FDA was expected to review the application in 2026. The announcement of 23 February 2026 said a decision was anticipated by late 2026. The third-quarter 2026 investor presentation, as summarised by Investing.com, lists a US regulatory decision for CagriSema in obesity in the fourth quarter of 2026, next to three other Novo Nordisk decisions due in the same quarter. Three statements across eleven months give one window: October to December 2026. About seven weeks of that window remain as this page is published.
Novo Nordisk's results announcement of 4 November 2026 adds the commercial half of the timeline. In it, chief executive Mike Doustdar says the company is "preparing for the US launch of CagriSema in early 2027, subject to regulatory approval". TheStreet reported on 5 November that Doustdar told Bloomberg the company hoped for approval at the end of this year and a launch at the start of next year, that production and staff training were already under way, that CagriSema would be offered direct to consumers from launch, and that Novo Nordisk would not disclose its pricing yet. An approval in December and a box on a pharmacy shelf in early 2027 are therefore two separate events, weeks or months apart.
Has the FDA set a decision date for CagriSema?
The FDA has published no decision date for CagriSema, and none of the three Novo Nordisk documents read for this piece names one. As a rule the agency does not announce target dates for applications under review; companies often do, and Novo Nordisk has given only a quarter. The review clock can still be estimated. Under the FDA's published performance goals for fiscal years 2023 to 2027, the agency aims to act on 90 percent of standard applications that contain a new molecular entity within 10 months of the 60-day filing date, which is about 12 months after submission. Cagrilintide has never been approved, so the combination falls in that group. Counted from 18 December 2025, a standard review points to mid-December 2026.
The mid-December estimate for CagriSema carries three caveats. First, it is arithmetic from a published goal, and Novo Nordisk has not said in these documents whether the review is standard or priority. A priority review would have reached its goal date around August 2026, which makes standard the reasonable reading. Second, the goal is a target the FDA commits to meet for 90 percent of applications, so a decision can come earlier or slip past the mark. Third, an FDA action is not always an approval: the agency can issue a complete response letter asking for more data, which would move the timeline into 2027 or later. Websites that print a specific day for the CagriSema decision are printing a guess, because no primary source gives one.
An approval letter in December would answer when. It would leave open what CagriSema costs, who covers it and which dose becomes the standard.
What did the CagriSema trials show?
CagriSema's application rests on two 68-week phase 3 trials, REDEFINE 1 and REDEFINE 2, both published online in the New England Journal of Medicine on 22 June 2025. REDEFINE 1 randomised 3,417 adults with obesity, or overweight with a related condition, and without diabetes. Average weight loss at week 68 was 20.4% with CagriSema and 3.0% with placebo, a difference of 17.3 percentage points, counting every participant whether or not they stayed on treatment. REDEFINE 2 randomised 1,206 adults with type 2 diabetes in 12 countries and reported 13.7% with CagriSema against 3.4% with placebo. Novo Nordisk's filing announcement also gives the REDEFINE 1 figure for participants who stayed on treatment: 22.7% against 2.3%.
| Trial | Who and how long | Compared with | Average weight loss |
|---|---|---|---|
| REDEFINE 1 | 3,417 adults without diabetes, 68 weeks | Placebo | 20.4% vs 3.0% |
| REDEFINE 2 | 1,206 adults with type 2 diabetes, 68 weeks | Placebo | 13.7% vs 3.4% |
| REDEFINE 4 | 809 adults with obesity, 84 weeks, open label | Tirzepatide 15 mg | 20.2% vs 23.6% (primary endpoint not achieved) |
| REDEFINE 9 | Adults with obesity, lower-dose CagriSema, 68 weeks | Not stated in the announcement | 21% |
| REIMAGINE 5 | Adults with type 2 diabetes and obesity, lower-dose CagriSema, 60 weeks | Tirzepatide 5 mg | 12.4% vs 9.1% |
Sources: N Engl J Med 2025;393:635-647 and 648-659; Novo Nordisk announcements of 23 February 2026 and 4 November 2026. Figures count all randomised participants where the source says so.
The side-effect record of CagriSema in those trials is dominated by the gut. In REDEFINE 1, gastrointestinal adverse events were reported by 79.6% of participants on CagriSema and 39.9% on placebo, and the journal describes them as mainly transient and mild to moderate. Novo Nordisk's filing announcement breaks that down as nausea in 55% against 12.6%, constipation in 30.7% against 11.6% and vomiting in 26.1% against 4.1%, with 5.9% of the CagriSema group stopping treatment because of adverse events against 3.5% on placebo. In REDEFINE 2 the gastrointestinal figure was 72.5% against 34.4%, and 8.4% against 3% stopped treatment. The FDA's reviewers will weigh those rates. This page reports them and draws no conclusion about any individual.
Is CagriSema better than Zepbound (tirzepatide)?
CagriSema did not match tirzepatide, the active ingredient in Zepbound, in the one trial that compared the two at full strength. REDEFINE 4 was an open-label, 84-week trial in 809 adults with obesity, announced by Novo Nordisk on 23 February 2026. Average weight loss was 20.2% with CagriSema and 23.6% with tirzepatide 15 mg when every participant was counted, and 23.0% against 25.5% among those who stayed on treatment. The trial was designed to show that CagriSema was not inferior, and Novo Nordisk's own headline says the primary endpoint was not achieved. The only full-strength head-to-head ended 3.4 percentage points in tirzepatide's favour. The FDA filing is based on REDEFINE 1 and REDEFINE 2, which were complete before that result arrived.
The lower-dose CagriSema data released since February point the other way, in a narrower comparison. Novo Nordisk's announcement of 4 November 2026 reports that CagriSema at 1.0 mg of each component produced 21% weight loss at week 68 in REDEFINE 9. It also reports that in REIMAGINE 5, in adults with type 2 diabetes and obesity, the same lower dose produced 12.4% weight loss against 9.1% for tirzepatide 5 mg, with a non-inferior reduction in HbA1c at week 60. Tirzepatide 5 mg is the lowest of that medicine's maintenance strengths, so the result says little about the 15 mg comparison above. Two more readouts are scheduled: REDEFINE 11 in the first half of 2027 and a high-dose trial in the first half of 2028.
Can you get CagriSema or cagrilintide before approval?
CagriSema cannot be legally prescribed or dispensed in the United States before approval, outside a clinical trial, and cagrilintide is closed to compounding pharmacies. The FDA's page on unapproved GLP-1 drugs, current as of 1 October 2026, states: "Retatrutide and cagrilintide cannot be used in compounding under federal law". The agency's reason is that they are not components of FDA-approved drugs and have not been found safe and effective for any condition. That puts cagrilintide in a different position from the six peptides in the HHS draft policy of 30 October 2026, explained in Are peptides legal now?. Products sold online as cagrilintide or as "CagriSema" are not Novo Nordisk's medicine and have not been reviewed by the FDA, a problem covered in Are research peptides safe?.
Does losing to tirzepatide change the FDA decision on CagriSema?
The strongest objection to the emphasis of this piece is that REDEFINE 4 is irrelevant to approval, and on the narrow question the objection holds. The FDA approves a drug when the evidence shows it is safe and effective for its proposed use, and the law does not require a new medicine to beat the market leader. CagriSema's application is built on placebo-controlled trials in which it produced 20.4% and 13.7% average weight loss, with a statistically significant difference from placebo in both. On that reading, the head-to-head result is a commercial problem for Novo Nordisk and no obstacle at the agency, and the December window stands.
That objection is right about the FDA decision and incomplete about what follows it. Coverage and price are negotiated with trial data on the table, and insurers will have REDEFINE 4 in front of them. Novo Nordisk's chief executive has said the price will reflect the value the drug provides, without giving a number. The company is also already testing a lower dose and a higher one. In Ozemback's reading, that is unusual for a product still waiting for its first approval, and it suggests the launch formulation is a starting point. An approval letter in December would answer when. It would leave open what CagriSema costs, who covers it and which dose becomes the standard.
So when will CagriSema be available, in short?
CagriSema is under FDA review and has no public decision date. Novo Nordisk filed on 18 December 2025, points to a decision in the fourth quarter of 2026, and says it is preparing a US launch in early 2027 if the drug is approved. The standard review clock lands in mid-December 2026, and a request for more data would push everything later. In trials, CagriSema produced 20.4% average weight loss against placebo and less than tirzepatide 15 mg in a direct comparison. Cagrilintide cannot be compounded under federal law. Ozemback will update this page when the FDA acts, and the newsletter below carries each regulatory change as it is published.
Sources
- Novo Nordisk, Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues, news release, 18 December 2025. www.novonordisk.com
- Novo Nordisk, CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved, company announcement No 13/2026, 23 February 2026. www.novonordisk.com
- Novo Nordisk, financial report for the first nine months of 2026, company announcement No 65/2026 (Form 6-K), 4 November 2026. www.sec.gov
- Investing.com, Novo Nordisk Q3 2026 slides: sales recover, outlook raised on GLP-1 growth, November 2026 (summary of the investor presentation). uk.investing.com
- Garvey WT et al., Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1), N Engl J Med 2025;393:635-647, published online 22 June 2025. pubmed.ncbi.nlm.nih.gov
- Davies MJ et al., Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes (REDEFINE 2), N Engl J Med 2025;393:648-659, published online 22 June 2025. pubmed.ncbi.nlm.nih.gov
- FDA, PDUFA reauthorization performance goals and procedures, fiscal years 2023 through 2027 (review goals for NME NDAs). www.fda.gov
- FDA, FDA's concerns with unapproved GLP-1 drugs used for weight loss, content current as of 1 October 2026. www.fda.gov
- TheStreet (via Yahoo Finance), Novo CEO gives key update on when its next obesity drug could launch, 5 November 2026 (reports Mike Doustdar's Bloomberg interview of 4 November). finance.yahoo.com
